GEN1047 for Solid Tumors - First in Human (FIH) Trial
Phase 1/2 Terminated
179 enrolled
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Phase 1/2 Terminated
5 enrolled
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
HeartPhone Cancer Survivors Trial 2019
Phase 1/2 Terminated
2 enrolled 6 charts
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Phase 1/2 Terminated
3 enrolled 8 charts
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
34 enrolled 15 charts
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Néo-APBI-01
Phase 1/2 Terminated
362 enrolled
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Phase 1/2 Terminated
8 enrolled
AMEERA-1
Phase 1/2 Terminated
136 enrolled 60 charts
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
Phase 1/2 Terminated
1 enrolled 5 charts
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Phase 1/2 Terminated
2 enrolled 6 charts
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Phase 1/2 Terminated
10 enrolled 15 charts
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
Phase 1/2 Terminated
9 enrolled 21 charts
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
Phase 1/2 Terminated
9 enrolled 5 charts
MGC018 With or Without MGA012 in Advanced Solid Tumors
Phase 1/2 Terminated
143 enrolled 33 charts
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 23 charts
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Phase 1/2 Terminated
5 enrolled
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Phase 1/2 Terminated
6 enrolled 11 charts
AVID100 in Advanced Epithelial Carcinomas
Phase 1/2 Terminated
49 enrolled 19 charts
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Phase 1/2 Terminated
10 enrolled 11 charts
neoBREASTIM
Phase 1/2 Terminated
2 enrolled
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Phase 1/2 Terminated
9 enrolled 7 charts
ELONA
Phase 1/2 Terminated
4 enrolled
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
Phase 1/2 Terminated
13 enrolled 18 charts
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Phase 1/2 Terminated
15 enrolled
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
40 enrolled 20 charts
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase 1/2 Terminated
222 enrolled 49 charts
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Phase 1/2 Terminated
6 enrolled
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
177 enrolled 25 charts
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
70 enrolled 24 charts
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Phase 1/2 Terminated
46 enrolled
CONTRAST
Phase 1/2 Terminated
18 enrolled
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Phase 1/2 Terminated
5 enrolled 6 charts
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Phase 1/2 Terminated
7 enrolled
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Phase 1/2 Terminated
9 enrolled 18 charts
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1/2 Terminated
3 enrolled 6 charts
JAVELIN Medley
Phase 1/2 Terminated
409 enrolled 108 charts
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
Phase 1/2 Terminated
3 enrolled 9 charts
ORCHID-1
Phase 1/2 Terminated
26 enrolled
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Phase 1/2 Terminated
3 enrolled